[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"OMass Therapeutics Australia Proprietary Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100655184","phase-1-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-oms1620-100655184",false,"NCT07811089","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620","A Randomized, Phase 1, Double-blind, Single and Multiple-Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMS1620 in Healthy Participants","Key Inclusion Criteria:\n\n* Body mass index (BMI) 18.0 to 32.0 kg\u002Fm2 (inclusive) and weight ≥45.0 kg\n* Females must be either postmenopausal, surgically sterile or consistently use highly effective methods of contraception from 30 days prior to Day -1 until at least 30 days after the end of the study.\n* Females must not be pregnant or lactating\n* Males participants who are sexually active with female partners who are females of childbearing potential must use at least two medically effective methods of contraception from Screening through 90 days after the last dose of study drug\n* Medically healthy with no significant medical history, physical examination, laboratory, vital signs, or ECG findings, as deemed by the Investigator or qualified designee\n\nKey Exclusion Criteria:\n\n* Use of systemic glucocorticoid therapies within 3 months prior to Screening or use of local glucocorticoid therapies (nasal, topical or inhaled) within 1 month prior to Screening\n* Use of mineralocorticoid therapies within 3 months prior to Screening\n* Current use of oral hormonal contraceptives. Extended cycle (e.g., ≥3 month) injectable, or implantable hormonal contraceptives are permissible, provided the cycle will not end during the conduct of the study\n* Any other condition or prior therapy, that, in the opinion of the Investigator, interferes with the participant's ability to safely complete the study or adhere to study requirements",true,"ALL","18 Years","55 Years",{"count":21,"type":22},84,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this study is to explore the safety, drug concentrations and effects on adrenal gland hormones after a single dose or multiple doses of OMS1620 in healthy participants. In addition, the effect of food on drug concentrations will also be tested.",[28],"Congenital Adrenal Hyperplasia (CAH)","NOT_YET_RECRUITING","2026-09-05",{"date":32,"type":33},"2026-09-09","ACTUAL",{"date":35,"type":22},"2026-09",{"date":37,"type":22},"2027-06",{"name":39,"class":40},"OMass Therapeutics Australia Proprietary Ltd","INDUSTRY",""]